{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:11:42Z","timestamp":1787170302522,"version":"build-2736575974"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.2169\/internalmedicine.8392-21","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T17:08:26Z","timestamp":1642007306000},"page":"2263-2271","source":"Crossref","is-referenced-by-count":7,"title":["Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose"],"prefix":"10.2169","volume":"61","author":[{"given":"Kana","family":"Kubota","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University, Japan"},{"name":"Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iekuni","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ueno","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University, Japan"},{"name":"Ueno Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gurion R, Raanani P, Vidal L, Leader A, Gafter-Gvili A. First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis. Acta Oncol (Stockholm, Sweden) 55: 1077-1083, 2016.","DOI":"10.1080\/0284186X.2016.1201214"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46: 903-975, 2015.","DOI":"10.1183\/13993003.01032-2015"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53: 1801913, 2019.","DOI":"10.1183\/13993003.01913-2018"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hughes TP, Laneuville P, Rousselot P, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica 104: 93-101, 2019.","DOI":"10.3324\/haematol.2018.188987"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Phan C, Jutant EM, Tu L, et al. Dasatinib increases endothelial permeability leading to pleural effusion. Eur Respir J 51: 1701096, 2018.","DOI":"10.1183\/13993003.01096-2017"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 126: 3207-3218, 2016.","DOI":"10.1172\/JCI86249"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transpl 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29: 1123-1132, 2015.","DOI":"10.1038\/leu.2015.36"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Short NJ, Kantarjian H, Jabbour E, Ravandi F. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best Pract Res Clin Haematol 30: 193-200, 2017.","DOI":"10.1016\/j.beha.2017.05.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shamroe CL, Comeau JM. Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother 47: 1540-1546, 2013.","DOI":"10.1177\/1060028013501144"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nature Biotechnol 25: 1035-1044, 2007.","DOI":"10.1038\/nbt1328"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125: 2128-2137, 2012.","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. El-Dabh A, Acharya D. EXPRESS: pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulm Circ 9: 2045894019865704, 2019.","DOI":"10.1177\/2045894019865704"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Seegobin K, Babbar A, Ferreira J, Lyons B, Cury J, Seeram V. A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib. Pulm Circ 7: 808-812, 2017.","DOI":"10.1177\/2045893217733444"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Quilot FM, Georges M, Favrolt N, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J 47: 676-679, 2016.","DOI":"10.1183\/13993003.01110-2015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90: 1060-1064, 2015.","DOI":"10.1002\/ajh.24174"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 34: 2333-2340, 2016.","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fox LC, Cummins KD, Costello B, et al. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Adv 1: 802-811, 2017.","DOI":"10.1182\/bloodadvances.2016003889"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nishimori M, Honjo T, Kaihotsu K, et al. Dasatinib-induced pulmonary arterial hypertension treated with upfront combination therapy. Case Rep Cardiol 2018: 3895197, 2018.","DOI":"10.1155\/2018\/3895197"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hong JH, Lee SE, Choi SY, et al. Reversible pulmonary arterial hypertension associated with dasatinib for chronic myeloid leukemia. Cancer Res Treat 47: 937-942, 2015.","DOI":"10.4143\/crt.2013.155"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 50: 1700217, 2017.","DOI":"10.1183\/13993003.00217-2017"},{"key":"22","unstructured":"22. Morishita S, Hagihara M, Itabashi M, et al. Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia. Rinsho ketsueki (Jpn J Clin Hematol) 57: 999-1003, 2016."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/15\/61_8392-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T01:17:52Z","timestamp":1715217472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/15\/61_8392-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":22,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8392-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"8392-21"}}